Literature DB >> 6470723

Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia.

W H Sherman, M R Olarte, G McKiernan, K Sweeney, N Latov, A P Hays.   

Abstract

Plasma exchange was used to treat 10 patients with polyneuropathy and a monoclonal antibody (plasma cell dyscrasia). Six patients had improvement of the neuropathy, while three patients had stabilisation of the neuropathy during plasma exchange. The patients who improved maintained a 64% or greater decrease in the monoclonal antibody between exchanges. Patients with axonal polyneuropathy as well as patients with demyelinating polyneuropathy recovered some neurologic function. With cessation of plasma exchanges, the monoclonal antibody titre approached pre-treatment levels and the neuropathy progressed. Plasma exchange was effective in rapidly lowering the level of monoclonal antibody and allowing for some recovery of neurologic function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470723      PMCID: PMC1027944          DOI: 10.1136/jnnp.47.8.813

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  NEUROLOGIC COMPLICATIONS OF MYELOMATOSIS.

Authors:  A SILVERSTEIN; D E DONIGER
Journal:  Arch Neurol       Date:  1963-11

2.  Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide.

Authors:  H Fowler; M Vulpe; G Marks; C Egolf; P C Dau
Journal:  Lancet       Date:  1979-12-01       Impact factor: 79.321

3.  Polyneuropathy in Waldenström's macroglobulinaemia.

Authors:  H Iwashita; A Argyrakis; K Lowitzsch; F W Spaar
Journal:  J Neurol Sci       Date:  1974-03       Impact factor: 3.181

4.  Myeloma neuropathy. Successful treatment of two patients and review of cases.

Authors:  L E Davis; D B Drachman
Journal:  Arch Neurol       Date:  1972-12

5.  The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation.

Authors:  J Salvaggio; P Arquembourg; J Bickers; D Bice
Journal:  Int Arch Allergy Appl Immunol       Date:  1971

6.  Paraproteinaemia in neurological disease: incidence, associations, and classification of monoclonal immunoglobulins.

Authors:  S N Kahn; P G Riches; J Kohn
Journal:  J Clin Pathol       Date:  1980-07       Impact factor: 3.411

7.  Monoclonal IgM kappa antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis.

Authors:  W H Sherman; N Latov; A P Hays; M Takatsu; R Nemni; G Galassi; E F Osserman
Journal:  Neurology       Date:  1983-02       Impact factor: 9.910

8.  Myeloma neuropathy: passive transfer from man to mouse.

Authors:  U A Besinger; K V Toyka; A P Anzil; A Fateh-Mognadam; R Rouscher; K Heininger
Journal:  Science       Date:  1981-08-28       Impact factor: 47.728

9.  Metabolism of human gamma-macroglobulin (IgM) in normal man.

Authors:  K B Jensen
Journal:  Scand J Clin Lab Invest       Date:  1969-10       Impact factor: 1.713

10.  Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.

Authors:  M C Dalakas; W K Engel
Journal:  Ann Neurol       Date:  1981       Impact factor: 10.422

View more
  15 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

3.  The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.

Authors:  K B Yeung; P K Thomas; R H King; H Waddy; R G Will; R A Hughes; N A Gregson; S Leibowitz
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

4.  Proximal motor neuropathy, IgA paraproteinaemia and anti-myelin-associated glycoprotein reactivity.

Authors:  T Hemachudha; P Phanuphak; K Phanthumchinda; S Kasempimolporn
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

Review 5.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

Review 6.  Plasma exchange in neurological diseases.

Authors:  P O Behan; W M Behan
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

Review 7.  Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy.

Authors:  R G Miller
Journal:  West J Med       Date:  1994-05

8.  Treatment of peripheral neuropathies.

Authors:  M Hallett; D Tandon; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

9.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

10.  IgG monoclonal paraproteinaemia and peripheral neuropathy.

Authors:  A F Bleasel; S H Hawke; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.